Clinical Trial Update: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of QL1101 with JS001 in patients with pMMR/MSS refractory metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• JS001 (PD-1 inhibitor)
• QL1101 (bevacizumab biosimilar)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Status: UNKNOWN